NeoGenomics to take advantage of thermo –


FT. MYERS, FL / ACCESSWIRE / December 10, 2021 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing and global contract research services in oncology, has announced that it will use Thermo Fisher Scientific’s Ion Torrent Genexus System, the first turnkey solution from Next Generation Sequencing (NGS) that automates the sample-to-report workflow to deliver results in as little as a single day, in a phase 1 study sponsored by the pharmaceutical industry.

As part of the preclinical research investigation, NeoGenomics will benefit from early access to the new Oncomine Myeloid Assay GX v2 test from Thermo Fisher to validate the test on the Genexus system. Thermo Fisher introduced the Oncomine GX v2 myeloid test at 63e American Society of Hematologists (ASH) Annual Meeting and Exhibition in Atlanta December 11-14. The test is designed to optimize the detection of variants, covering key genes and fusions across the myeloid cancer spectrum.

Mark Mallon, CEO of NeoGenomics, said: “We have worked with Thermo Fisher Scientific in several genomics initiatives and are excited to leverage their Genexus system to deliver comprehensive genomic data at unprecedented speed. By reducing the time to results from weeks to days, we can ensure researchers have the data they need to accelerate progress as they seek to develop much-needed myeloid cancer treatments. to come up. “

“Myeloid cancers such as acute myeloid leukemia present unique challenges due to their heterogeneity and the complexity of their samples,” said Garret Hampton, president of clinical sequencing and oncology, Thermo Fisher Scientific. “NGS allows researchers to profile all key mutations simultaneously, saving time compared to sequential testing on a single gene. By combining the speed of the Genexus system with the expertise and data services of NeoGenomics, we hope to advance discoveries that will inform future therapeutic development for patients who desperately need new treatment options. “

NeoGenomics continues to be a leader with lightning-fast NGS options for oncology research and was one of the early adopters of the Genexus system. It is also one of the first oncology reference laboratories to offer the OncomineDx target test in their menu of clinical diagnostic tests.

About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetic testing and information services, providing one of the world’s most comprehensive oncology-focused test menus for physicians to help diagnose and treat cancer. Cancer. The company’s pharmacy services division serves pharmaceutical clients in clinical trials and drug development.

NeoGenomics is committed to connecting patients with life-changing therapies and trials. We believe that together, with our partners, we can help cancer patients today and the next person diagnosed tomorrow. By fulfilling these commitments, NeoGenomics adheres to all relevant data protection laws, provides transparency and choice to patients regarding the processing and use of their data through our Privacy Practices Notice, and has invested in cutting-edge technologies to ensure that the data we keep is secure. always.

Based in Fort Myers, Florida, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Cambridge, UK; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical companies, integrated service delivery networks and managed care organizations in the United States and pharmaceutical companies in Europe and Asia.

Forward-looking statements

Certain information in this press release constitutes forward-looking statements for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified by the use of words such as “anticipate,” ” expect “,” plan “,” could “,” could “,” could “,” be able “,” believe “,” estimate “,” foresee “,” objective “,” project “,” plan “, “” And other words with similar meanings. These forward-looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in forward-looking statements due to the Company’s ability to continue winning new customers, responding to the effects of COVID-19, propose new types of tests, integrate its acquisitions and implement its business plan, as well as additional factors discussed under the heading “Risk factors” and elsewhere in the annual report of the company on Form 10-K filed with the SEC on February 25, 2021, as this information has been updated in subsequent SEC filings. . Accordingly, this press release should be read in conjunction with the Company’s periodic filings with the SEC. NeoGenomics regularly posts information that may be important to investors in the “Investor Relations” section of its website at The Company encourages investors and potential investors to periodically check the NeoGenomics website for important information about NeoGenomics.

Forward-looking statements speak only as of the date on which such statements are made (unless another date is indicated) and should not be relied on at any later date. Although the Company may choose to update forward-looking statements at any time in the future, it specifically disclaims any obligation to do so.

For more information, please contact:

Doug brown
Director of Strategy and Business Development
T: 239.768.0600 x2539
M: 704.236.2064
[email protected]

Charlie eidson
Director, Investor Relations and Corporate Development
T: 239.768.0600 x2726
M: 952.221.8816
[email protected]

THE SOURCE: NeoGenomics, Inc.

See the source version on

Source link


Comments are closed.